Tag Archives: EU

Europe Leads Generic-Drugs Assessment Project

The European Union’s  decentralized procedure is to be used by international regulatory agencies as a model for facilitating generic-drug application assessments, as part of the International Generic Drug Regulations Pilot (IGDRP) project. At the request of a generic-drug company, the EU will share assessment reports in real time with collaborating international regulatory agencies. According to […]
Posted in Europe, Global | Also tagged , | Leave a comment

The European Parliament’s New Term: What Can We Expect?

As Europe departs for its annual holiday—sacrosanct, even amid the continuing economic woes, the multiple crises in the Middle East, and the dark mysteries of Russia’s intentions in its former satellites—the question remains unresolved as to what to expect from the new European Parliament in the new term. Philip Ward considers the options in this […]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , | Leave a comment

European Pharma Races to Catch Up with Data Protection

The European Union’s struggle to bring its data protection rules into the 21st century continues—haltingly—as the EU itself enters its new era, with a new European Parliament, a new President-designate of the European Commission, and a new European Commission due to take office in November. This has left the pharmaceutical sector, already out of breath […]
Posted in Europe, Global, Guest Blog, Technology | Also tagged , , , | Leave a comment

EFPIA’s “Integrated Strategy”: Out of the Frying Pan, Into the Fire?

It’s difficult to open an email or an envelope in Brussels these days without yet another agenda falling out of it, carrying the promise of a new start. With a new European Parliament installed, a new European Commission president appointed and a new Commission on the way, and guarded optimism that the worst of the […]
Posted in Europe, Global, Op-Ed, Regulatory | Also tagged , , | Leave a comment

EMA Responds Robustly to Conflict-of-Interest Claims

By Philip Ward, Applied Clinical Trials. The European Medicines Agency (EMA) has insisted that the concerns raised about its scientific advice given to pharmaceutical companies stem from a flawed understanding of the activities of the agency and its partners in this area.
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , , | Leave a comment
  • Categories

  • Meta